Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Arcturus Therapeutics Holdings Inc. before investing. In this article, we go over ...

Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with cystic fibrosis—an outcome William Blair found “potentially promising.” ...

Analysts' ratings for Arcturus Therapeutics (NASDAQ:ARCT) over the last quarter vary from bullish to bearish, as provided by 5 analysts. The following table summarizes their recent ratings, shedding ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...

After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF ...

Arcturus stock sinks 56% after cystic fibrosis drug shows no clear lung function gains. Phase 2 data finds ARCT-032 safe but lacking strong efficacy signals so far. Company plans higher-dose, 12-week ...

Arcturus Therapeutics (ARCT) shares ended the last trading session 7.7% higher at $23.16. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

We may earn commission from links on this page, but we only recommend products we love. Promise. I spend a good chunk of my week at the office, and honestly, it’s literally freezing in there. Like, it ...

AbbVie, Capstan Therapeutics and other defendants were hit with a trade secret lawsuit on Sept. 23 in California Southern District Court. The suit, filed by Wilson Sonsini Goodrich & Rosati on behalf ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...